wmm, Author at Invivoscribe

About wmm

This author has not yet filled in any details.
So far wmm has created 67 blog entries.

ASH

wmm2025-02-27T18:42:26-08:00December 6th, 2024|Conferences|

The 48th Annual Meeting of the Molecular Biology Society of Japan

wmm2025-02-27T18:42:17-08:00December 3rd, 2024|Conferences|

JSPHO Annual Meeting

wmm2025-02-27T18:41:02-08:00November 19th, 2024|Conferences|

Medica

wmm2025-02-27T18:42:10-08:00November 17th, 2024|Conferences|

AMP

wmm2025-02-27T18:42:00-08:00November 11th, 2024|Conferences|

ICCS

wmm2025-02-27T18:41:50-08:00October 26th, 2024|Conferences|

ESMO

wmm2025-02-27T18:40:39-08:00October 17th, 2024|Conferences|

JSH Annual Meeting

wmm2025-02-27T18:40:28-08:00October 12th, 2024|Conferences|

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

wmm2024-10-08T03:14:44-07:00October 8th, 2024|2024 Press Releases, Press Releases|

JACLaS

wmm2025-02-27T18:40:14-08:00October 3rd, 2024|Conferences|

JCA Annual Meeting

wmm2025-02-27T18:40:02-08:00September 25th, 2024|Conferences|

ECP

wmm2025-02-27T18:39:37-08:00September 6th, 2024|Conferences|

SOHO

wmm2025-02-27T18:39:10-08:00September 3rd, 2024|Conferences|

CGC

wmm2025-02-27T18:38:41-08:00August 3rd, 2024|Conferences|

ADLM

wmm2025-02-27T18:38:21-08:00July 27th, 2024|Conferences|

26th JSLH

wmm2025-02-27T18:37:05-08:00July 26th, 2024|Conferences|

32nd Japanese Society for Gene Diagnosis and Therapy

wmm2025-02-27T18:36:44-08:00July 11th, 2024|Conferences|

The 65th Annual Meeting of the Japanese Society of Lymphoma Research & Hematopathology

wmm2025-02-27T18:36:29-08:00July 3rd, 2024|Conferences|

ICML

wmm2025-02-27T18:13:50-08:00June 17th, 2024|Conferences|

EHA

wmm2025-02-27T18:12:54-08:00June 12th, 2024|Conferences|

ASCO

wmm2025-02-27T18:12:22-08:00May 30th, 2024|Conferences|

15th JSH International Symposium

wmm2025-02-27T18:11:12-08:00May 16th, 2024|Conferences|

ASGCT

wmm2025-02-27T18:10:50-08:00May 13th, 2024|Conferences|

JAMT

wmm2025-02-27T18:10:35-08:00May 10th, 2024|Conferences|

BSH

wmm2025-02-27T18:10:11-08:00April 27th, 2024|Conferences|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

About wmm

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.